TILVANCE-301: A new hope for melanoma patients in Israel
Melanoma that has spread is still very hard to treat. Standard drugs like pembrolizumab (Keytruda®) help many people, but not everyone. Sometimes the tumor keeps growing. Because of this, a new global study called TILVANCE-301 is now running — and Israel is part of it.
What’s different about this trial?
It combines two treatments:
- Pembrolizumab, the well-known immunotherapy.
- Lifileucel (TIL therapy), made from your own immune cells. Doctors take a small piece of the tumor, grow billions of those “fighter cells” in a lab, and return them to you.
Think of it as giving your body back its own army, just much stronger.
How it’s tested
People are randomly placed into two groups. One gets pembrolizumab alone. The other gets both lifileucel and pembrolizumab. Doctors then check which way works better — how many patients respond and how long the effect lasts.
Who may join
Adults with advanced melanoma that cannot be removed by surgery. Patients should be in fairly good overall condition. Certain cases, like eye melanoma or active brain metastases, usually cannot enter.
Why Israel?
Because Israel is one of the few countries where this trial is open. Patients here can get cutting-edge therapy, guided by leading oncologists. And if the cancer grows during standard treatment, there is even an option to move to the lifileucel arm later.
How to apply
If you or your family member want to be checked for this study, send us your medical history — from diagnosis until today. Our doctors will review it, and if the criteria fit, you will get an official invitation.
📞 Tel: +972-73-374-6844
📱 WhatsApp: +972-52-337-3108
📧 Email: [email protected]
